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ABSTRACT
Thymidylate synthase (TS) catalyzes the reductive transfer of a methyl group from
N5,N10-methylenetetrahydrofolate

(CH2-THF)

to

dUMP,

forming

dTMP

and

dihydrofolate (DHF). It is generally accepted that inhibition of the enzyme leads to a
deficiency of dTMP, followed by genome damage and programmed cell death. As such,
TS has long been viewed as an important target of anti-neoplastic agents, such as 5fluorouracil (5-FU) and raltitrexed (RTX), which lead to inhibition of the enzyme.
Oxidative stress is well-recognized as having a central role in cellular response to a
number of DNA damaging agents, and may be a proximate cause of therapy-induced cell
death.

Despite such recognition, little detail exists on the origin and regulation of

reactive oxygen species (ROS) during TS-directed chemotherapy. We have undertaken a
detailed examination of the origin, nature, and role of ROS in cell death mediated by TS
inhibitors. In colon tumor cell line HCT116, fluorescence detection of H2O2 and O2●(using H2DCFDA and DHE, respectively) showed that profound increases in ROS levels
occur during drug exposure.

These increases are attenuated by treatment with the

antioxidant N-acetylcysteine (NAC), by addition of thymidine to the medium, and by TS
overproduction, indicating that it is indeed TS inhibition and the resulting dTMP
deficiency that is responsible for the increased ROS levels. Apoptotic indices, as
measured by TUNEL assays, parallel changes in ROS levels, i.e., they are induced in
response to drug, and are inhibited by NAC. We have identified NADPH oxidase (NOX)
as the primary source of increased ROS following exposure to TS-directed agents, as
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indicated by the observation of decreased ROS production and apoptotic indices in
presence of NOX inhibitors. We have found that in response to TS inhibitors, NOX
enzyme activity increases in association with induction of the transcript for p67phox,
which specifically regulates the NOX2 isoform. These effects were reduced by thymidine
and by TS overproduction. To substantiate and expand results obtained from HCT116,
we used other colorectal cancer cells, including HCT15, SW480, DLD-1, LoVo, MOSER
and LS180. We have determined that colon cancer cells exhibit diverse responses in both
basal and drug-inducible levels of apoptosis, NOX activity and mRNA of NOX2
regulatory subunits, implicating the heterogeneity in colorectal cancer cells. To
understand whether other factors are involved in TS inhibitors-mediated ROS generation,
we investigated the effects of NFκB on drug-mediated ROS accumulation in HCT116
cells. Loss of NFκB has no effects on increase in NOX activity mediated by TS
inhibitors. It has no effects on drug-induced ROS and p67phox mRNA expression, either.
However, we have determined that NFκB is an important suppressor for basal ROS
formation in correlation with the induction of p67phox mRNA. Based on these results, we
conclude that augmentation of NOX2 activity via induction of p67phox mRNA expression
is the proximate cause of programmed cell death elicited by dTMP deficiency in HCT116
cells. NFκB has no role in such effects. Each colorectal cancer cells might have different
mechanism to undergo ROS-mediated cell death.
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GENERAL INTRODUCTION
Colorectal cancer (CRC) is a disease that starts in glands in the lining of the colon (the
longest part of the large intestine) or the rectum (the last several inches of the large
intestine closest to the anus). It is the third most common cancer worldwide and the
disease rate is the highest in developed countries, including the USA, Australia, Canada
and Europe. Worldwide, every year, more than 1.2 million individuals develop CRC,
accounting for a mortality over 600,000 and 9.7% of total cancer deaths (Ferlay et al.,
2010). According to the National Cancer Institute, estimated new cases in the USA in
2012 numbered 103,170 in the colon and 40,290 in the rectum, leading to approximately
51,690 deaths from CRC (www.cancer.gov/cancertopics/types/colon-and-rectal). The
development of inflammatory bowel disease (ulcerative colitis), having a family history
of CRC and age over 50 increase the lifetime risk of colorectal carcinogenesis (Keane
and Johnson, 2012).

Treatment of CRC depends upon the degree of progression of the cancer and can
be curative if caught in an early stage (Stein et al., 2011; Cunningham et al., 2010).
Treatments may include surgery (removal of cancer cells), chemotherapy (to kill cancer
cells) and radiation (to destroy cancerous tissue). The prognosis still remains modest in
spite of recent advances at the molecular level of CRC. Survival rate (5 years) has not
changed with the recent advances and chemotherapy still depends upon the mainstay of
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treatment (Platell et al., 2011; Lucas et al. 2011). There are several drugs, including 5fluorouracil (5-FU), irinotecan, and oxaliplatin that can be used to treat CRC. These
drugs are often combined to get more efficient chemotherapy. Fluoropyrimidines, in
particular, 5-FU and its nucleoside analog 5’-fluoro-2’-deoxyuridine (FdUrd), are widely
used agents and remain a major component of many standard regimens for various cancer
types (Figure I1) (Soong and Diasio, 2005; Milano et al. 2004). Metabolism and
cytotoxic mechanisms of 5-FU involve multiple pathways. These pathways show antiproliferative effects of 5-FU and its metabolites through incorporation into DNA or RNA
and/or inhibition of thymidylate synthase (TS) (Berger and Berger, 2006; Wyatt and
Wilson,

2009).

Investigating

and

understanding

potential

determinants

of

fluoropyrimidine metabolism could help to establish a strong rationale for improving
therapeutic response. TS inhibition is known as a major mechanism of 5-FU cytotoxicity;
the degree of its inhibition could provide potential indicators of efficacy (Kessel et al.,
1966, Myers et al., 1975).

TS Inhibition and Cancer Chemotherapy
TS (EC 2.1.1.45) catalyzes the reductive transfer of a methyl group from N5, N10methylenetetrahydrofolate (CH2-THF) to the C5 of deoxyuridylate monophosphate
(dUMP) to form thymidylate (dTMP) whose subsequent phosphorylation to dTTP
provides a precursor for DNA synthesis (Figure I2) (Carreras and Santi, 1995). In the
absence of exogenous thymidine, the enzyme is the sole source of thymidylate. To form
dTMP, a covalent ternary complex is formed by the enzyme, dUMP and CH2-THF. 5-FU
and FdUrd are converted to the efficient TS inhibitor 5-fluoro-2’-deoxyuridylic acid
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(FdUMP), which is an analogue of the natural TS substrate dUMP, and forms an
inhibitory ternary complex with the enzyme and CH2-THF (Santi et al., 1987; Longley et
al., 2003). This inhibitory complex is comprised of two covalent linkages as in the
catalytic complex, resulting in considerably stable inhibition of the enzyme. Inhibition of
TS blocks dTMP production and leads to genome damage through misincorporation of
uracil into DNA, and shuts off DNA synthesis and repair, triggering apoptosis
(Danenberg, 1977; Spears et al., 1988; Krokan et al., 2002; Longley et al., 2003). As a
consequence, TS is an important target for anticancer chemotherapy by anti-neoplastic
agents, including 5-FU and antifolate inhibitors, in treatment of colorectal and other
tumors (Takezawa et al., 2010).

The important role of the folate co-substrate in TS activation prompted structural
investigations into the synthesis and design of antifolates (folate analogs) that inhibit TS
(Jackman et al., 1996). Antifolates might potentially be more useful than dUMP analogs
because TS-inhibitiory antifolates are not sensitive to the increased levels of dUMP
arising from the inhibition. dUMP analogs compete with elevated dUMP to bind the
enzyme’s active site (Gmeiner, 2005; Winder and Lenz, 2010). Larger structure gives a
chance to antifolates for various chemical modifications. Addition to these advantages,
they have different toxicity profiles from fluoropyrimidines, particularly 5-FU, that has
RNA-mediated effects making contribution to cytotoxicity as well. Several antifolates,
including ZD1694 (raltitrexed (RTX), tomudex) (Figure I1), CB3717, LY231514,
GW1843 and AG337, are currently being evaluated for the treatment of cancer (McGuire,
2003; Gmeiner, 2005; Takemura and Jackman, 1997; Bertino, 1997).
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Fluoropyrimidines have been integrated into numerous clinical trials and have
exhibited anti-tumor activity in the chemotherapy of various neoplasms. In particular, the
antimetabolite 5-FU is widely used in chemotherapy of CRC and remains one of the most
common anticancer drugs in use today (Soong et al., 2008). At current doses, adjuvant
treatment with 5-FU shows clinical response in stage III CRC patients with ~10-15%
survival rate (Moertel et al., 1995). Incremental evidence shows that 5-FU-based
therapies are beneficial for stage II colon carcinoma patients as well (Midgley and Kerr,
2005). Biomodulation of the anti-cancer effects of 5-FU has been attempted and studies
based upon known metabolic interactions have improved the drug-based therapy. One of
the current standard treatment options for advanced CRC is usage of 5-FU in
combination with leucovorin (LV) (N6-formyl tetrahyrofolate), a reduced folate, that is
converted to CH2-THF and enhances the interaction between FdUMP and TS, prolonging
the inhibition (Sotos et al., 1994; Berg et al., 2002). Other drug combinations, such as 5FU/ LV with platin analogue oxaliplatin (FOLFOX), or DNA topoisomerase I inhibitor
irinotecan (FOLFIRI) have enhanced the therapeutic capability of 5-FU-LV treatment
(Berg et al., 2002; Folprecht and Kohne, 2004; Vincenzi et al., 2004; Rose et al., 2002;
Wilson et al., 2006; Davis et al., 1995).

The X-ray structure studies of TS ternary complexes from E. coli and human have
been useful in designing novel TS-inhibitory drugs (Matthews et al., 1990; Montford et
al., 1990; Schiffer et al., 1995). These approaches have given rise to delineation of the
chemistry of the enzyme’s active site, the interaction of enzyme and ligands, and the
understanding of the structural basis for TS mutations that generate resistance to TS
inhibitors (Almog et al., 2001; Phan et al., 2001; Tong et al., 1998; Fantz et al., 2000).
4

These efforts are accelerated by the availability of more sophisticated computational
tools.

Cellular Response to TS Inhibitors

CRC is a malignant disease that results from accumulation of genetic and epigenetic
alterations that lead to derangements in cell proliferation, and differentiation, giving rise
to transformation of normal colonic epithelium to colon adenocarcinoma (Vogelstein et
al., 1988). Many studies have shown that alterations in TS gene expression and structure
are strong markers for the prediction of response to 5-FU-based chemotherapy in CRC
(Popat et al., 2004; Popat et al., 2005; Pullarkat et al., 2001). TS overexpression can
mediate drug resistance due to elevated mRNA and protein levels (Jenh et al., 1985;
Berger et al., 1985). Sensitivity to TS-targeting drugs can be modified by several events
including altered metabolism of 5-FU, diminished cellular uptake and polyglutamylation
of anti-folates and elevated drug efflux (Gorlick and Bertino, 1999; Berg et al., 2002;
Mader et al., 1998). It is essential to comprehend the multiple mechanisms of action of
TS inhibitors in order to understand drug resistance.

There are other factors and mechanisms that can play roles in drug-based
cytotoxicity following TS inhibition. These act downstream of the inhibition to regulate
either apoptosis or DNA repair, and include apoptotic enzyme caspases (Backus et al.,
2003), death receptors FAS and KILLER/DR5 (Petak et al., 2000; Wang and El-Deiry,
2004), tumor suppressor protein p53, cell-cycle kinase inhibitor p21 (Berg et al., 2002;
Van Triest et al., 2000; Geller et al., 2004), the thymine glycosylase MBD-4 (Millar et
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al., 2002; Sansom et al., 2003), SMUG1 glycosylase, (Wyatt and Wilson, 2009), and the
mismatch repair protein MLH-1 (Meyers et al., 2005; Wyatt and Wilson, 2009).

It has been suggested that generation of reactive oxygen species (ROS) is one of
the consequences of TS inhibition. ROS production is increased by 5-FU, and the
inhibition of ROS reverses its cytotoxicity (Alexandre et al., 2006b, Hwang et al., 2007;
Laurent et al., 2005; Hwang et al., 2001; Shibata et al., 2008; Ueta et al., 1999). As a
result of drug treatment, ROS are released and partially trigger apoptosis in cancer cells
(Gallego et al., 2008). Chemoresistance in these cells is induced by high levels of antioxidants (Ramanathan et al., 2005; Derdak et al., 2008). Accordingly, a significant
strategy involves modulation of oxidative stress in cancer cells in order to sensitize them
to anticancer drugs and generate novel protocols for improved clinical responses
(O’Dwyer et al., 1996; Bougnoux et al., 2009).

A Biomarker of Cell Death Induced by TS Inhibitors: ROS

ROS is a common term that delineates a group of reactive chemical species that originate
from the incomplete reduction of oxygen, including radical oxidants such as superoxide
anion (O2.-), the hydroxyl radical (OH.) and stable non-radical oxidants such as hydrogen
peroxide (H2O2). They are formed by several different mechanisms. They can be an
inevitable byproduct of cellular respiration in mitochondria due to electron leakage. They
may be synthesized by devoted enzymes like NADPH oxidase, xanthine oxidase,
myeloperoxidase, or through the transition metals such as iron (Fe) and copper (Cu).
Finally, they can result from the interplay of biological molecules in response to ionizing
radiation (Balaban et al., 2005; D’Autreaux and Toledano, 2007). ROS regulate various
6

signal transduction pathways through reaction with proteins, lipids, genes and
transcription factors, resulting in modification of their structures and modulation of their
functions (Birben et al., 2012; Trachootham et al., 2009). They also regulate intracellular
signaling pathways mediated by cytokines, leading to removal of pathogens (Klebanoff,
2005). If ROS levels elevate severely, it might inexorably cause oxidative damage,
following cell death. In contrast, slight elevation of ROS might lead to temporary cellular
alteration (Perry et al., 2000). So, it is crucial to maintain ROS homeostasis in normal cell
proliferation and survival.

ROS may function as a double-edged sword. A mild increase in ROS levels may
promote cell growth and survival, whereas excessive ROS may overwhelm the
antioxidant resistance of the cell (Schafer and Buettner, 2001). The shift between
oxidants and antioxidant in response to excessive ROS is named “oxidative stress”,
which contributes to several pathological diseases such as cancer, hypertension, diabetes,
asthma (Valko et al., 2006; Kerr et al., 1999; Asami et al., 1997; Andreadis et al., 2003).
It has been observed that diverse types of cancer cells have higher ROS levels than their
normal counterparts (Szatrowski and Nathan, 1991; Kawanishi et al., 2006). Under
physiological conditions, the balance between pro-oxidants (ROS production) and
antioxidants (ROS detoxification) is controlled by maintaining basal level of ROS,
sustaining redox homeostasis in normal cells (Tiligada, 2006). Tolerance to ROS stress
can be provided by antioxidant system until it reaches to the cell-death threshold.
Upregulation of ROS in cancer cells because of genetic instability and metabolic
abnormalities could promote an adaptation to oxidative stress by inducing antioxidant
mechanisms, keeping cells below the toxic threshold (Pelicano et al., 2004).
7

Consequently, antioxidant-targeting agents that produce further ROS makes cancer cells
more dependent upon antioxidant capacity and more vulnerable to oxidative stress than
normal cells. This causes ROS levels to increase above a cellular tolerability threshold,
resulting in cell death (Figure I3) (Schumacker, 2006; Trachootham et al., 2009). Such
vulnerability to oxidative stress represents an Achilles heel that offers potential strategies
to direct anti-cancer agents.

The fate of cancer cells is thus bound up by the level of ROS induced by
anticancer drugs. Upon genome damage, including that caused by TS inhibitors, cell
cycle is arrested by the machinery called the checkpoint response (Zhou and Elledge,
2000). The response could be either repair of the damage or annihilation of the cell by
apoptosis. Several studies have shown that genome damage induced by TS inhibitors, 5FU and FdUrd, causes G1/S and G2/M arrest, and activates the checkpoint signaling
enzymes like Chk1, ameliorating the DNA damage (Robinson et al., 2006; Xiao et al.,
2006; Parsels et al., 2004). However, the checkpoint response can escalate the damage if
it is excessive. Oxidative stress via TS inhibitors may lead to this checkpoint response.
As such, the checkpoint response to TS inhibitors can occur in two opposite ways: cell
survival through DNA repair and cell death via augmentation of genome damage induced
by ROS. In both scenarios, a decline in the number of damaged cells occurs. Efficiency in
treatment of TS inhibitors depends on the balance between these two responses.

As stated above, it has recently been shown that oxidative stress is a significant
cellular response to anticancer drugs, including TS inhibitors (Alexandre et al., 2006b;
Hwang et al., 2007; Laurent et al., 2005; Hwang et al., 2001). However, mechanisms by
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which these drugs induce ROS generation in cancer cells are not well defined. It is known
that the activity of ROS generating enzymes like NADPH oxidases is increased to kill
cancer cells (Kumar et al., 2008; Lambeth, 2004).

NADPH Oxidases (NOX): A Potential Target of TS Inhibitors

The generation and accumulation of ROS can physiologically occur as a by-product of
functioning or damaged mitochondria, by enzyme systems such as peroxisomal oxidases
and lipoxygenases, and in response to ROS-producing environmental exposures or
inflammatory conditions (Balaban et al., 2005; Schrader and Fahimi, 2004). In contrast,
the family of NADPH oxidases (NOX) produce ROS as their primary and sole function
(Bedard and Krause, 2007; Lambeth, 2004). This enzyme family occurs as multi-protein
complexes consisting of a membrane-spanning catalytic NOX subunit and regulatory
subunits that are localized in the cytosol and the membrane. The NOX family is
comprised of seven isoforms: NOX1-5 and dual oxidases (Duox), Duox1 and Duox2
(Lambeth, 2004; Bedard and Krause, 2007; Altenhöfer et al., 2012).
All NOX family members are trans-membrane proteins that generate O2.- by
transporting electrons (e-) across the membrane to reduce oxygen (O2). NOX4 appears to
generate essentially H2O2 (Takac et al., 2011). Expression and regulation of NOX
isoforms vary in tissues and are differentially localized in subcellular compartments
(Brown and Griendling, 2009; Altenhöfer et al., 2012). It has been reported that all NOX
isoforms bind to membrane and/or cytosolic proteins to mediate their activation. Among
them, NOX1 and NOX2 subunits are the best characterized. Catalytic NOX1 and NOX2
subunits bind to a common protein, p22phox in the membrane, forming a membrane
9

complex termed flavocytochrome b558. The flavocytochrome b558 complex of NOX1
binds to NOX activator 1 (NOXA1) and NOX organizer 1 (NOXO1), while the complex
of NOX2 binds the respective subunits p67phox and p47phox, as well as subunit p40phox.
Rac, a small GTPase, binds to NOXA1 and p67phox upon activation of enzymes (Hayes
and Knaus, 2013; Wingler et al., 2011; Altenhöfer et al., 2012).

NOX2, also known the phagocyte NOX (neutrophils and macrophages) or
gp91phox, was the prototypical NADPH oxidase (Babior et al., 2002). In recent past, its
biochemical properties have been comprehensively studied (Robinson et al., 2004;
Vignais, 2002). Under normal conditions, NOX2 and p22phox are localized in the plasma
membrane or the membrane of intracellular vesicles in neutrophils, existing in close
association. Cytosolic regulatory subunits (p40phox, p47phox and p67phox) are triggered by
signaling enzymes such as protein kinases and lipid-metabolizing enzymes.
Phosphorylation by protein kinases results in conformational changes that cause the
movement of cytosolic subunits p40phox, p47phox and p67phox to the membrane, and
binding to flavocytochrome b558. Assembly of subunits involves binding of p22phox to the
bis-SRC-homology 3 (SH3) domain of p47phox and of NOX2 to the activation domain
(AD) of p67phox. RAC also binds to the tricodecapeptide (TPR) domain of p67phox due to
a conformational change. Assembly of all subunits brings about the activation of NOX2
catalytic function, involving the transportation of electrons from cytoplasmic NADPH to
FAD, first and second heme groups, respectively and finally to extracellular or
phagosomal oxygen to produce O2.- (Figure I4) (Hayes and Knaus, 2013; Bedard and
Krause, 2007; Lambeth, 2004).
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It has been suggested that human tumor cells generate their characteristically
elevated ROS levels by NOX, indicating the contribution of this enzyme to
carcinogenesis for various types of cancer (Kamata, 2009; Laurent et al., 2008; Lassegue
and Griendling, 2010; Banfi et al., 2000). This contribution might be because of ROSdependent signaling and promotion of cell growth. In colorectal cancer, ROS generation
occurs within both colon epithelial cells themselves and derivation from NOX1 and
NOX2 enzymes (Kikuchi et al., 2000; Perner et al., 2003). The excessive amount of ROS
derived by NOX1 and NOX2 raises the question to which extent overactivation is
balanced by the antioxidant capability of cells. It has been suggested that NOX2-derived
ROS may have a significant role in the defense system against inflammatory colon cancer
(McKenzie et al., 1996; Huang et al., 2004).

NOX1 and NOX2 are potentially important targets of TS inhibitors that induce
ROS formation, since they are highly expressed in colon tissue (Hwang et al., 2001;
Juhasz et al., 2009). For decades, TS inhibitors have been widely used in chemotherapy
of colorectal cancer because of their strong cytotoxic impacts. Greater efficacy in causing
apoptotic programmed cell death may be achieved by activating ROS-producing systems.
Therefore, the NOX enzyme family by virtue of its ability to produce the excessive ROS
in colon cancer cells may be an attractive target of TS inhibitors.

The primary aim of the studies presented in this work was to increase an
understanding of the role of ROS in cell death induced by TS inhibitors. Particularly, the
goal was to examine the origin and nature of ROS produced in response to TS inhibitors.
The specific goals were to: (1) determine ROS generation in response to TS inhibitors,
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(2) identify the source of ROS formed by TS inhibitors and (3) determine the role of ROS
in cell death induced by TS inhibitors in human colon cancer cell lines.

Figure I 1. Chemical structure of TS inhibitors; 5-FU, FdUrd and RTX.

Figure I 2. Thymidylate synthase (TS) reaction. TS catalyzes transfer of a methyl group
from N5, N10-methylenetetrahydrofolate (CH2-THF) to deoxyuridylate monophosphate
(dUMP) to form deoxythymidylate monophosphate (dTMP). Leucovorin is converted to
CH2-THF and enhances the interaction between FdUMP and TS.
12

Figure I 3. Redox homeostasis in normal and cancer cells. Normal cells have a low
level of basal ROS to sustain redox homeostasis by virtue of balance between prooxidants (ROS induction) and antioxidants (ROS elimination). In cancer cells, redox
homeostasis is sustained with high pro-oxidants resulting from metabolic abnormalities
and high antioxidants resulting from high levels of basal ROS, holding ROS levels below
the toxic threshold. Further ROS increase by TS inhibitors results in an imbalance
favoring pro-oxidants, thereby making cancer cells vulnerable to cell death.

Figure I 4. ROS production by assembly of NOX2 regulatory proteins. Activation of
NOX2 system mediated by protein kinases and guanine-nucleotide exchange factor
(GEF) results in the assembly of flavocytochrome b558, p22phox and NOX2, and cytosolic
regulatory proteins, p40phox, p47phox, p67phox and RAC-GTP. Phosphorylation of p47phox
allows it to bind p22phox, leading to binding of p67phox to NOX2 and binding of p40phox to
lipids. RAC binding to p67phox helps to assemble the active complex. The activation
domain of p67phox induces e- transfer from NADPH to O2 (the rate limiting step) to
generate O2.-.
13

CHAPTER 1
THE EFFECTS OF TS INHIBITORS ON ROS GENERATION
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1.1. INTRODUCTION
Anticancer drugs including TS inhibitors kill cancer cells by disrupting genome stability
and metabolic normality (Pelicano et al., 2004). In general, TS inhibitors lead to genome
damage via dTMP depletion and loss of DNA synthesis (Longley et al., 2003; Santi et al.,
1987). There are other cellular responses to drug-based cytotoxicity following TS
inhibition, regulating either apoptosis or DNA repair (Backus et al., 2003, Van Triest et
al., 2000; Wyatt and Wilson, 2009).

It has been previously demonstrated that oxidative stress is an important cellular
response to TS inhibitors (Hwang et al., 2007; Laurent et al., 2005; Hwang et al., 2001).
ROS have an essential role in regulation of diverse signal transduction pathways. They
react with many molecules such as protein, lipids to modify their structures, resulting in
alteration of their functions. Therefore, maintaining ROS homeostasis in normal cell
survival is so important. It is known that cancer cells have more ROS than normal cells,
making them vulnerable to oxidative stress (Trachootham et al., 2009).

It has been previously shown that 5-FU, in a p53-dependent manner, induces the
mitochondrial enzyme ferredoxin reductase (FR) that transfers electrons from NADPH to
cytochrome P450, resulting in the generation of ROS in mitochondria (Hwang et al.,
2001; Liu and Chen, 2002). It has also been demonstrated that colorectal tumors have
about 2-fold more FR expression than normal cells, indicating contribution of FR and
oxidative stress to tumor development (Yu et al., 2003).
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Another determinant of 5-FU-mediated oxidative stress is spermidine/spermine
N1-acetyltransferase (SSAT), which is a rate-limiting enzyme in polyamine catabolism
that forms H2O2 as a by-product. 5-FU induces SSAT in a p53-dependent manner and
acts synergistically with SSAT inducers like N1, N11-diethylnorspermine (DENSPM) to
kill colon carcinoma cells. These synergistic effects are abolished by antioxidants (Allen
et al., 2007; Choi et al., 2005).

Recently, a novel mitochondrial protein called reactive oxygen species modulator
1 (Romo1) was identified and shown to be highly expressed in various cancer cells
(Chung et al., 2006). Following upregulation of Romo1 in cancer cells by 5-FU, ROS
formation is elevated. This 5-FU-based induction of Romo1 is abolished by Romo1
siRNA (Hwang et al., 2007).

Overexpression of superoxide dismutase (SOD) increases H2O2 levels in human
cancer cells. It has been demonstrated that two nonpeptidyl mimics of SOD, copper [II]
diisopropylsalicylate (CuDIPS) and manganese [III] tetrakis-(5,10,15,20)-benzoic acid
porphyrin (MnTBAP), enhance the cytotoxicity of anticancer drugs through
augmentation of H2O2 levels (Laurent et al., 2005). In addition to these redox modulators,
mangafodipir, a chelate of manganese [II] and the ligand fodipir, a vitamin B6 derivative,
increases H2O2 generation via its SOD-, glutathione reductase- and catalase-like
properties. It was shown that 5-FU-induced ROS production and glutathione depletion
was elevated by CuDIPS, MnTBAP and mangafodipir in CT26 mouse colon cancer cells,
and

inhibited by N-acetylcysteine (NAC), an antioxidant that has catalase- and

glutathione reductase-like effects on redox metabolism (Alexandre et al., 2006a).
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Activation of manganese superoxide dismutase (Mn-SOD) by 5-FU was seen in
squamous cell carcinoma (SCC) cells (OSC-1 to OSC-4). Furthermore, 5-FU induced the
intracellular H2O2 and O2.- levels and decreased the mitochondrial membrane potential
(Δψm) in these cells, indicating action of 5-FU at multiple steps of redox metabolism
(Ueta et al., 1999).

It was shown that 5-FU treatment induced mitochondrial oxidative stress in
human colon cancer cell lines HT-29 and SW-620, by virtue of increased mitochondrial
lipid peroxidation and protein carbonylation and decreased levels of uncoupling protein-2
(UCP2) and -5 (UCP5), mitochondrial ROS suppressors (Santandreu et al., 2011).
Overall, accordingly, these observations have implied that oxidative stress has an
important role in the cytotoxic response to TS inhibitors.

The mechanism that drives the accumulation of ROS by TS inhibitors is not well
defined. It is of value to know the type of ROS induced by TS inhibitors and whether or
not this induction is mediated by various TS inhibitors. Here, we demonstrate that TS
inhibitors, 5-FU, FdUrd and RTX, induce generation of H2O2 and O2.-, which is inhibited
by the antioxidant NAC. We also demonstrated that the pro-oxidant aminotriazole (ATZ),
a catalase inhibitor, induces H2O2 generation, but not apoptosis.

The best known action of TS inhibitors is the inhibition of TS enzyme. The
dependency of ROS accumulation on TS inhibition is not known. Here, we demonstrate
that exogenous supplement of thymidine inhibits TS inhibitor-mediated ROS formation,
indicating the dependency of ROS induction on TS inhibition. In order to verify this
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dependency, we also use TS-overexpressing cells (Berger et al., 1988) that are resistant to
TS inhibitors.

1.2. RESULTS
ROS formation is induced by TS inhibitors

ROS are formed by a variety of mechanisms, including mitochondrial electron leakage,
oxidative enzymes like NADPH oxidase, xanthine oxidase, metal (Fe, Cu) transition, etc.
(Balaban et al., 2005; D’Autreaux and Toledano, 2007). Previous work has shown that 5FU increases levels of ROS in various cancer cells by virtue of its capability to modulate
expression of ROS-inducer proteins like Romo1, UCP2 and enzymes like FR, SSAT,
MnSOD (Hwang et al., 2001; Yu et al., 2003; Allen et al., 2007; Hwang et al., 2007; Ueta
et al., 1999; Santandreu et al., 2011). In order to substantiate results found in other
laboratories, 5-FU and other two TS inhibitors, the fluoropyrimidine FdUrd and the
antifolate RTX, were added to subconfluently plated HCT116 cells, for 24 hours, after
which the cells were harvested and stained with ROS indicator dyes, H2DCFDA (H2O2
marker) and DHE (O2.- marker). The 24h time point and 10µM drug concentration were
selected due to the observed high levels of H2O2 in response to FdUrd (Figure 1.1 C).

Cells treated with TS inhibitors exhibited increased H2O2 formation, as indicated
by green fluorescence resulting from the interaction of H2DCFDA and H2O2. Also, the
drug induced O2.- formation, as indicated by red fluorescence resulting from the
interaction of DHE and O2.- (Figure 1.1 A). In order to verify these findings, cells stained
by H2DCFDA and DHE were assayed by flow cytometry. As observed in fluorescence
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microscopy, cells treated with drugs exhibited a shift to the right, indicating increased
H2O2 and O2.- generation, thereby implicating TS inhibitors as a ROS inducer in colon
cancer cells (Figure 1.1 A).

In order to modify intracellular redox status, cells were treated with NAC for 24
hours, and analyzed by fluorescence microscopy and flow cytometry. In presence of
NAC, TS inhibitors have no effect on H2O2 and O2.- generation, indicating the inhibition
of ROS production by NAC (Figure 1.1 B). We conclude that all three drugs upregulated
both H2O2 and O2.- formation in HCT116 cells, and that this upregulation was
ameliorated by NAC (Figure 1.1 A and B). Cells were also treated with ATZ, a catalase
inhibitor that increases H2O2 levels, for 24 hours. Fluorescence microscopy and flow
cytometry assays were used to analyze H2O2 generation. Combination of ATZ to FdUrd
has no effects on H2O2 generation, meaning that both ATZ and FdUrd may induce H2O2
generation from the same source in HCT116 cells (Figure 1.5 A).

ROS generation is due to TS inhibition

TS is the sole source of dTMP whose subsequent phosphorylation provides dTTP, a
precursor for DNA synthesis (Carreras and Santi, 1995). Inhibition of TS enzyme
abolishes dTMP production and results in genome damage by virtue of misincorporation
of uracil into DNA, promoting apoptosis and loss of DNA synthesis (Danenberg, 1977;
Spears et al., 1988; Krokan et al., 2002; Longley et al., 2003). In presence of exogenous
thymidine, dependency on TS diminishes, decreasing the cytotoxic effects of TS-directed
drugs. In order to delineate the role of TS inhibition on ROS generation, thymidine was
supplemented to HCT116 cells for 24 hours. Cells treated with thymidine exhibited no
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induction of either H2O2 and O2.- following treatment with in combination of 5-FU,
FdUrd and RTX compared to cells treated with drugs alone (Figure 1.2 A and B).

To extend this conclusion, we utilized FdUrd-resistant cell line HCT116/200 that
overproduces a variant structural form of TS, causing decreased affinity for FdUMP and
CH4-THF. HCT116/200 cells are treated with 5-FU, FdUrd and RTX for 24 hours. They
showed only about two fold induction of ROS formation in treatment of drugs, thereby
implicating TS inhibition as important in ROS production mediated by TS inhibitors
(Figure 1.3 A and B).

The role of ROS in drug-mediated apoptosis

Previous work from our lab demonstrated that the apoptotic response to
increasing concentrations of TS inhibitors never exceeds 10-25% in HCT116 cells
(Barbour and Berger, 2008). Mechanisms of cell death following dTMP deprivation in
cells treated with TS inhibitors have been studied for decades. A number of such studies
have focused on signaling pathways such as the FAS pathway with caspase activation
(Longley et al., 2003; Petak et al., 2000); however, others have examined pathways that
are caspase-independent (Fiers et al., 1999; Broker et al., 2005). In order to determine
direct role of ROS augmentation on cell death, HCT116 cells were treated with 5-FU,
FdUrd or RTX, with and without NAC for 48 hours, and apoptotic indices were
determined by TUNEL assay. From each treatment, pictures were taken of representative
areas of the cultures and at least 500 cells both apoptotic (dark brown) and non-apoptotic
(purple) were counted (Figure 1.4 A). NAC inhibited drug-mediated apoptosis by more
than 50% compared to cells treated with drugs alone, thereby implicating a contribution
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of ROS accumulation to apoptosis (Figure 1.4 B). Cells were also treated with TS
inhibitors, with and without ATZ for 48 hours to assay apoptotic response by TUNEL
assay. ATZ slightly increased apoptosis itself; however, it has no effect on drug-mediated
apoptosis, thereby implicating that ROS generation by itself does not induce apoptosis
(Figure 1.5 B). Some other consequence of exposure to TS inhibitors, in addition to ROS,
is necessary.

1.3. DISCUSSION
The current data shows that TS inhibitors, fluoropyrimidine 5-FU, FdUrd and antifolate
RTX increase the levels of ROS, as indicated by DCF (H2O2) and HE fluorescence (O2.-),
in colon cancer cells (Figure 1.1 A). This drug-mediated ROS augmentation was
abrogated with a general antioxidant, NAC, confirming oxidative stress caused by TS
inhibitors (Figure 1.1 B). Supplementation of thymidine abolished ROS formation
induced by TS inhibitors, showing the relation between TS inhibition and ROS induction.
This suggests that dTMP depletion by TS inhibition brings about oxidative stress that is
counteracted

by

thymidine

addition.

Furthermore,

fluoropyrimidine-resistant

HCT116/200 cells, overexpressing TS protein, produce only moderate increases in ROS
following with TS inhibitors. This resistance decreases drug-mediated oxidative stress,
indicating a strong connection between oxidative stress and TS inhibition.

Previous work from our lab demonstrated that apoptosis induced by TS inhibitors
reaches only 10-25% in HCT116 cells even they are treated with drug concentrations far
in excess levels (Barbour and Berger, 2008). Our results indicate that apoptosis mediated
by TS inhibitors is diminished above 50% by NAC, thereby implicating importance of
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oxidative stress in drug-mediated cell death. Additionally, apoptosis is not induced by
ATZ either alone or in combination with TS inhibitors. These results show that ROS is
necessary for apoptosis following drug exposure, but it is not sufficient to kill cells.

In summary, my data suggests that TS inhibitors induce ROS generation in a TS
dependent manner and that this induction sensitizes cells to apoptotic death. This gives a
general indication about how drug-mediated ROS induction takes place. In order to
understand the mechanism behind the induction, it is necessary to determine the source of
ROS source, as affected by TS inhibitors.
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Figure 1.1. NAC inhibits ROS generation mediated by TS inhibitors. (A) HCT116
cells were treated with 10µM FdUrd, 10µM 5-FU and 1µM RTX for 24 hours and then
stained by 5µM H2DCF-DA and DHE. ROS detection was done in both fluorescence
microscopy and flow cytometry. Pictures represent H2O2 formation (green) and O2.- (red).
(B) 1mM NAC is combined with TS inhibitors and treated to cells for 24h. (C) HCT116
cells were treated with increasing numbers of FdUrd concentrations, 1nM, 10nM,
100nM, 1µM, 10µM and then stained by 5µM H2DCF-DA to measure dose response by
flow cytometry. Bars represent fold increase of H2O2 (DCF fluorescence) and O2.- (HE
fluorescence) formation ± SEM from 3 experiments (** p<0.01).
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Figure 1.2. Rescue of drug-induced ROS by thymidine. (A) HCT116 cells were treated
with 10µM FdUrd, 10µM 5-FU and 1µM RTX for 24 hours and then stained by 5µM
H2DCF-DA and DHE. (B) 10µM Thy is combined with TS inhibitors and treated to cells
for 24h. Bars represent fold increase of H2O2 (DCF fluorescence) and O2.- (HE
fluorescence) formation ± SEM from 3 experiments (** p<0.01)
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Figure 1.3. Rescue of drug-induced ROS by TS overproduction. (A) HCT116 cells
were treated with 10µM FdUrd, 10µM 5-FU and 1µM RTX for 24 hours and then stained
by 5µM H2DCF-DA and DHE. (B) HCT116/200 cells were treated with TS inhibitors for
24h. Bars represent fold increase of H2O2 (DCF fluorescence) and O2.- (HE fluorescence)
formation ± SEM from 3 experiments (** p<0.01)
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Figure 1.4. Effects of NAC on drug-induced cell death. (A) HCT116 cells were treated
with 1mM NAC and 10µM 5-FU for 48 hours and then extents of apoptosis were
determined by TUNEL assay. Pictures for with and without (UT) 5-FU treatment and its
combination with 1mM NAC were taken under light microscopy at 400X. (B, C) 1mM
NAC combined with 10µM 5-FU, 100µM FdUrd and 1µM RTX treated to cells for 48
hours. Bars represent fold increase of apoptotic indices ± SEM from 3 experiments (*
p<0.05, ** p<0.01).
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Figure 1.5. ATZ induces H2O2 generation, but not apoptosis. (A) HCT116 cells were
treated with 10µM FdUrd and 1mM ATZ for 24 hours and then stained by 5µM H2DCFDA. ROS detection was done in both fluorescence microscopy and flow cytometry.
Pictures represent H2O2 formation (green). Bars represent fold increase of H2O2 (DCF
fluorescence) formation ± SEM from 3 experiments (* p<0.05, ** p<0.01). (B) HCT116
cells were treated in combination of 1mM ATZ with 10µM 5-FU, 100µM FdUrd and
1µM RTX for 48 hours and then extents of apoptosis were determined by TUNEL assay.
Bars represent fold increase of apoptotic indices ± SEM from 3 experiments.
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CHAPTER 2
ROS INDUCED BY TS INHIBITORS IS ASSOCIATED WITH UPREGULATION OF
PHOX

P67

SUBUNIT OF NADPH OXIDASE 2
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2.1. INTRODUCTION
In TS-directed therapy, the origin and regulation of ROS is not known (Hwang et
al., 2001; Liu and Chen, 2002; Yu et al., 2003; Allen et al., 2007; Choi et al., 2005;
Chung et al., 2006; Hwang et al., 2007; and Ueta et al., 1999). Work described in Chapter
1 revealed that NAC inhbits ROS generation mediated by TS inhibitors, but the origin of
ROS in response to TS inhibitors was not determined. Here, we show that the enzyme
NADPH oxidase (NOX) generate profound amount of ROS in response to TS inhibitors
in human colon cancer cells through an increase in NOX enzyme activity.

Expression of NOX isoforms is diverse in tissues (Brown and Griendling, 2009;
Altenhöfer et al., 2012). NOX1 and NOX2 could be important sources of ROS in
response to TS inhibitors since they are highly expressed in colon tissue (Hwang et al.,
2001; Juhasz et al., 2009). Here, we demonstrate expression of NOX1 and NOX2
subunits in human colon cancer cell, HCT116. Among all NOX regulatory subunits,
p67phox is the only one whose expression is increased by TS inhibitors, thereby indicating
that it may be a key subunit in activation of NOX2 in HCT116 cells following exposure
to TS inhibitors.
p67phox has an activation domain whose functional role is to interact with the
membrane-bound NOX2 subunit. Because of its significant role in activation, it is of
interest to examine whether it is responsible for ROS induction induced by TS inhibitors.
Here, we determined that NAC and NOX inhibitors abrogated the induction of p67phox
mRNA and protein levels, indicating the role of p67phox in drug-directed ROS generation.
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Furthermore, we show that the induction of mRNA and protein levels of p67phox was
abolished by TS overproduction or thymidine supplementation.

2.2. RESULTS
NOX inhibitors abolish ROS induction mediated by TS inhibitors

The sole function of NOX is formation of superoxide (Bedard and Krause, 2007;
Lambeth, 2004). It is suggested as a major source of ROS in human cancer cells (Kikuchi
et al., 2000; Perner et al., 2003); however, it is not known if it is a source of ROS in TStargeted therapy. To test whether NOX is involved in ROS generation in response to TS
inhibitors, we utilized pharmacologic NOX inhibitors, DPI, APO and VAS-2870. By
using fluorescence microscopy, we found that elevated levels of H2O2 in response to 5FU, FdUrd and RTX are abrogated by NOX inhibitors in HCT116 cells (Figure 2.1, 2.2
and 2.3 upper panel).
NOX inhibitors also reduce induction of O2.- formation by 5-FU, FdUrd and RTX
in HCT116 cells. Findings obtained from fluorescence microscopy were also verified by
flow cytometry (Figure 2.1, 2.2 and 2.3 lower panel).

NOX activity induced by TS inhibitors is reduced by NOX inhibitors, addition of
thymidine and TS-overproduction

After seeing the modulation of TS inhibitor-mediated ROS by NOX inhibitors, the
question of how do TS inhibitors mediate NOX-derived ROS was raised. To answer this
question, we tested whether TS inhibitors induce NOX enzyme activity. We utilized a
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chemiluminescence assay to measure NOX activity in cells exposed to TS inhibitors.
This activity assay does not distinguish NOX isoforms, meaning that all NOX isoforms
are responsible for measured activity levels. First, we used 5-FU and FdUrd to test
whether they activate the NOX enzyme. Following treatment with 5-FU and FdUrd,
NOX activity increased 5-6 folds in HCT116 cells; this increase was attenuated by DPI
treatment, showing a significant effect of TS inhibitors on NOX activity (Figure 2.4).

We next tested whether thymidine addition and TS overproduction modulate the
activation of NOX activity mediated by TS inhibitors. NOX activation by 5-FU and
FdUrd was decreased by thymidine addition and TS overproduction, thereby indicating
that the increase in NOX activity is due to TS inhibition (Figure 2.5).

In order to understand whether this activation of NOX activity occurs in cell lines
other than HCT116, we examine of NOX activity in response to 5-FU and FdUrd in
human colon cancer cell lines; SW480 and HCT15. Drug-induced NOX activation was
about the same for all 3 colon cancer lines; furthermore, the activation of NOX in all 3
cell types was diminished by specific NOX inhibitor, VAS-2870, thereby implicating
NOX as a main driver of ROS formation in response to TS inhibitors in human colon
cancer cells (Figure 2.6).

NOX inhibitors decrease cell death in response to TS inhibitors

As seen in Chapter 1, apoptotic indices by TS inhibitors are abrogated by NAC, showing
involvement of ROS in drug-mediated apoptosis. In order to determine whether NOX
inhibitors cause an effect on apoptosis induced by TS inhibitors, we treated HCT116 cells
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with DPI, APO and VAS-2870. As seen in Figure 2.7, DPI and APO abrogated cell death
in response to 5-FU, FdUrd and RTX by >80% (p<0.01). The specific NOX inhibitor
VAS-2870 decreased drug derived-apoptotic indices by about 50% (p<0.05), thereby
showing the contribution of NOX enzyme to apoptosis induced by TS inhibitors (Figure
2.7). Decrease in apoptotic indices mediated by TS inhibitors is more in treatment of DPI
and APO than that of VAS, implicating that there are other enzymes mediating druginduced apoptosis in addition to NOX enzyme.
Association of p67phox with NOX-derived ROS formation in response to TS
inhibitors

The NOX enzyme family comprises multi-protein complexes consisting of a membranespanning catalytic NOX subunit and regulatory subunits localized in both the cytosol and
the membrane. There are 7 members of the family: NOX1-5 and dual oxidases (Duox),
Duox1 and Duox2 (Lambeth, 2004; Bedard and Krause, 2007; Altenhofer et al., 2012).
It has shown that expression of NOX isoforms varies in tissues (Brown and
Griendling, 2009; Altenhöfer et al., 2012). In colon tissue, NOX1 and NOX2 are highly
expressed and may be important sources of oxidative stress following exposure to TS
inhibitors (Hwang et al., 2001; Juhasz et al., 2009). We tested whether NOX1 and NOX2
are targeted by TS inhibitors. To test this, HCT116 cells were treated with 5-FU and
microarray analysis was done to measure expression of various NOX1 and NOX2
subunits. We have found that about 3000 genes are differentially expressed in response to
5-FU. Among them, there are genes that are targeted by nuclear factor (erythroid-derived
2)-like 2 (Nrf2) whose antioxidant response is the major defense system against oxidative
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stress in human cells (Table 2.1). With the exception of p67phox, expression of all NOX1
and NOX2 subunits were unchanged by 5-FU (Figure 2.8). Similarly, mRNA levels
detected semi-quantitatively of all NOX1 and NOX2 subunits, except p67phox, were
unaltered by FdUrd treatment (Figure 2.9). Among all subunits, only mRNA levels of
p67phox was induced by about 28-fold (p<0.01) (Figure 2.10). Thus, p67phox subunit may
be a key regulator of NOX enzyme in response to FdUrd.
In order to determine if p67phox plays a role in NOX-derived ROS formation in
response to TS inhibitors, we treated HCT116 cells with FdUrd and NOX inhibitors and
determined mRNA levels of p67phox by quantitative PCR. As expected, mRNA levels of
p67phox induced by FdUrd were decreased by DPI, VAS-2870 and NAC, suggesting a
correlation between p67phox and NOX derived-ROS formation in response to FdUrd
(Figure 2.11 A).
In order to determine whether the induction of p67phox by FdUrd depends upon
TS, we added thymidine to growth medium and also used TS-overproducing cells.
Consistent with our previous results, thymidine addition and TS overproduction
attenuated p67phox induction (Figure 2.12 A). Consistent with mRNA levels, we also
measured protein levels of p67phox following FdUrd. NOX protein levels were increased;
this increase was markedly reduced by NAC, DPI, VAS-2870 and thymidine addition
(Figure 2.11 C and 2.12 C). Taken together, these results implicate NOX2 as a major
source and p67phox as a key regulator of ROS generation in response to TS inhibitors.
Activation of NOX enzyme and induction of p67phox in treatment of TS inhibitors depend
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on TS inhibition. This shows a correlation of NOX enzyme and p67phox in drug-induced
ROS generation.

2.3. DISCUSSION
Oxidative stress is an important cellular response to TS inhibitors (Hwang et al., 2001;
Laurent et al., 2005; Alexandre et al., 2006b; Hwang et al., 2007). As indicated in
Chapter 1, TS inhibitors increase ROS levels in HCT116 colon cancer cells and this
increase is associated with thymidine stress and cell death. However, the origin and
nature of ROS generation induced by TS inhibitors is unknown. NAC is a general
antioxidant, but provides no information on the source of ROS.

Here, we demonstrate that NOX inhibitors attenuate the induction of ROS
mediated by TS inhibitors, and decrease the activation of NOX enzyme induced by TS
inhibitors, implicating NOX as a major source of ROS production in response to TS
inhibitors. The activation of NOX enzyme in response to TS inhibitors showed the same
trend in 3 different human colon cancer cell lines, HCT116, HCT15 and SW480, thereby
implicating the common activation spectrum in distinct colon cancer cells. Additionally,
the induction of apoptosis by TS inhibitors is inhibited by NOX inhibitors, showing the
role of NOX in ROS-derived cell death.

We examined gene expression of NOX1 and NOX2 subunits in response to 5-FU
and found that the expression of p67phox is induced by 5-FU. Similarly, the mRNA level
of p67phox was induced in response to FdUrd.
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p67phox is the cytosolic subunit of the NOX2 enzyme and, during activation of the
enzyme, it interacts with the NOX2 subunit in the membrane via its functional activation
domain (Lambeth, 2004). We have shown that the activation of NOX by TS inhibitors
correlates with the induction of p67phox expression. The correlation between the inhibition
of drug-induced ROS and p67phox mRNA and protein by NAC and NOX inhibitors
suggests the role of p67phox in ROS formation in response to TS inhibitors. Examination
of mRNA levels of p67phox in addition of thymidine and TS overproduction also indicate
a possible role for p67phox in TS-directed therapy.
This study is the first to reveal the role of NOX2 with its cytosolic subunit p67 phox
in ROS generation and in cell death mediated by TS inhibitors in HCT116 cells.
Although further studies are necessary, NOX enzyme may be a novel source in the field
of cancer chemotherapy.
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Figure 2.1. DPI abrogates ROS generation induced by TS inhibitors. (A) HCT116
cells were treated with 10µM FdUrd, 10µM 5-FU and 1µM RTX for 24 hours and then
stained by 5µM H2DCF-DA and DHE. (B) 10µM DPI is combined with TS inhibitors
and treated to cells for 24h. Bars represent fold increase of H2O2 (DCF fluorescence) and
O2.- (HE fluorescence) formation ± SEM from 3 experiments (** p<0.01)
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Figure 2.2. APO reduces ROS generation mediated by TS inhibitors. (A) HCT116
cells were treated with 10µM FdUrd, 10µM 5-FU and 1µM RTX for 24 hours and then
stained by 5µM H2DCF-DA and DHE. (B) 1mM APO is combined with TS inhibitors
and treated to cells for 24h. Bars represent fold increase of H2O2 (DCF fluorescence) and
O2.- (HE fluorescence) formation ± SEM from 3 experiments (* p<0.05, ** p<0.01)
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Figure 2.3. VAS decreases ROS generation induced by TS inhibitors. (A) HCT116
cells were treated with 10µM FdUrd, 10µM 5-FU and 1µM RTX for 24 hours and then
stained by 5µM H2DCF-DA and DHE. (B) 10µM VAS is combined with TS inhibitors
and treated to cells for 24h. Bars represent fold increase of H2O2 (DCF fluorescence) and
O2.- (HE fluorescence) formation ± SEM from 3 experiments (* p<0.05, ** p<0.01).
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Figure 2.4. DPI decreases NOX activity increased by TS inhibitors. (A, B) HCT116
cells were treated with 10µM 5-FU and 10µM FdUrd for 24 hours and then were
subjected to NOX activity assay as described in “materials and methods”. 10µM DPI was
added to reaction buffer. Lucigenin derived chemiluminescence was measured by
luminometer. Bars represent fold increase of chemiluminescence ± SEM from 3
experiments (** p<0.01).

Figure 2.5. NOX activity increased by drugs depends upon TS inhibition. (A, B)
HCT116 cells were treated with both TS inhibitors (10µM 5-FU, 10µM FdUrd) and
10µM thymidine for 24 hours. HCT116/200 cells were treated with 10µM 5-FU, 10µM
FdUrd for 24 hours. NOX activity were measured by luminometer. Bars represent fold
increase of chemiluminescence ± SEM from 3 experiments (* p<0.05).
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Figure 2.6. VAS reduces NOX activity increased by drugs in colon cancer cell lines.
(A, B) HCT116, SW480 and HCT15 cells were treated with both TS inhibitors (10µM 5FU, 10µM FdUrd) and 10µM VAS for 24 hours. NOX activity were measured by
luminometer. Bars represent fold increase of chemiluminescence ± SEM from 3
experiments.
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Figure 2.7. NOX inhibitors decrease drug-induced cell death. (A, B) HCT116 cells
were grown in 10µM DPI (3h), 1mM APO (48h) and 10µM VAS (48h) with and without
10µM 5-FU, 100µM FdUrd and 1µM RTX for 48 hours. Extents of apoptosis were
determined by TUNEL assay. Cells were photographed at 400X. Bars represent fold
increase of apoptotic indices ± SEM from 3 experiments.
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Figure 2.8. Gene expression of NOX1 and NOX2 subunits in response to 5-FU.
HCT116 cells were treated in quadruplicate with ± 10µM 5-FU for 24h. cDNAs are
synthesized from isolated mRNA samples. T7 RNA polymerase was added to cDNA
samples to amplify original mRNA molecules and was added to cDNA samples and to
simultaneously incorporate cyanine 3- or cyanine 5-labeled CTP (cRNA) into the
amplification product. Labeled cRNA samples were hybridized to Agilent Human GE 4 x
44K v2 Microarrays at 65°C for 17 hours. Arrays were scanned using an Agilent DNA
Microarray Scanner System.
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Figure 2.9. mRNA levels of NOX1 and NOX2 subunits in response to FdUrd.
HCT116 cells were treated with ± 10µM FdUrd for 24h. Semi-quantitative RT-PCR was
used to determine relative levels of NOX1 and NOX2 subunit’s mRNAs in total RNA
isolated from cells. Indicated subunits were examined to show relative levels of mRNAs
in untreated and FdUrd treated cells. GAPDH was tested as a loading control.
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Figure 2.10. Only p67phox mRNA is induced in treatment of FdUrd. HCT116 cells
were treated with ± 10µM FdUrd for 24h. mRNA levels of NOX1 and NOX2 subunits
were assayed by qPCR using GAPDH as a loading control. Bars represent an average of
fold increase ± SEM from 2 separate experiments (** p<0.01).
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Figure 2.11. Expressions of p67phox mRNA and protein levels in treatment of FdUrd
and antioxidants. (A, B) HCT116 cells were cultured for 24h ± 10µM FdUrd and
addition of 1mM NAC (24h), 10µM DPI (3h), and 10µM VAS (24h). p67phox mRNA
levels were assayed by qPCR using GAPDH as a loading control. Bars represent an
average of fold increase ± SEM from 2 separate experiments (** p<0.01, * p<0.05). (C)
Protein levels of p67phox were determined in treatment of ± 10µM FdUrd for 24h and its
combinations with 1mM NAC (24h), 10µM DPI (3h), and 10µM VAS (24h).
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Figure 2.12. Addition of thymidine and TS overproduction decrease induction of
p67phox mRNA by FdUrd. (A, B) HCT116 cells were treated with ± 10µM FdUrd and
its combination with 10µM thymidine for 24h. HCT116/200 cells were treated with ±
10µM FdUrd for 24h. p67phox mRNA levels were assayed by qPCR. Bars represent an
average of fold increase ± SEM from 2 separate experiments (** p<0.01). (C) Protein
levels of p67phox were determined in treatment of ± 10µM FdUrd for 24h and its
combinations with 10µM Thy (24h).
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Table 2.1. 5-FU-regulated Nrf2 target genes in HCT116 cells

Nrf2 Target Genes
Aldehyde dehydrogenase 3 family, member A1
Aldo-keto reductase family 1, member B10
Aldo-keto reductase family 1, member C1
ATP-binding cassette, sub-family C, member 2
Growth arrest and DNA-damage-inducible, alpha
Heat shock 22kDa protein 8
Heme oxygenase 1
Serpin peptidase inhibitor, clade E, member 1
Spermidine/spermine N1-acetyltransferase 1
v-maf musculoaponeurotic fibrosarcoma oncogene homolog F
Cyclin-dependent kinase inhibitor 3
Glutamate-cysteine ligase, catalytic subunit
NFKB repressing factor
RAB11 family interacting protein 4
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Gene
Symbol
ALDH4A1
AKR1B10
AKR1C1
ABCC2
GADD45A
HSPB8
HMOX1
SERPINE1
SAT1
MAFF
CDKN3
GCLC
NKRF
RAB11FIP4

Fold
Change
2.0
up
6.4
up
2.3
up
2.6
up
2.1
up
2.8
up
2.0
up
6.0
up
2.5
up
2.1
up
2.2 down
1.8 down
1.8 down
2.6 down

CHAPTER 3
TS INHIBITOR-MEDIATED INDUCTION OF APOPTOSIS AND EXPRESSION OF
NOX SUBUNITS VARY IN COLORECTAL CANCER CELL LINES
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3.1. INTRODUCTION
Cancer laboratories establish a large number of human colorectal cancer cell lines from
surgical specimens in the pathology laboratories. Established and characterized cell lines
were classified into different groups based on their morphological features, growth rate,
karyotypes, ability to synthesize carcinoembryonic antigen (CEA), etc. (McBain et al.,
1984; Leibovitz et al., 1976). It has been shown that there is no correlation among these
classification parameters and that genetic alteration in each tumor is not similar,
implicating high levels of variability among the lines (Leibovitz et al., 1976). It has been
also shown that the individual colon cancer exhibit a broad range of morphological and
functional heterogeneity (McBain et al., 1984; Brattain et al., 1981). Cell lines may
undergo these changes during their long-term culture, suggesting that properties of the
cells may not reflect those of their original tumors (Brattain et al., 1981)

It has been shown that well-described colon cancer cells characterized in vivo and
in vitro with regard to drug response, genetic abnormalities, expression of cancerassociated genes, etc. display important differences in tumor growth and metastatic
capacity, leading to heterogeneity, possibly in a clinical relevant manner (Flatmark et al.,
2004). Studies done to characterize structural instability in chromosomes of colon cancer
cells revealed that it plays a significant role in the formation of genetic heterogeneity in
different colon cancer cell lines (Ribas et al., 2003). Heterogeneity resulting from any
system in cancer cells may bring about resistance to chemotherapeutic drugs (de Anta et
al., 2006).
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Heterogeneity is also apparent in apoptosis of different colon cancer cells and is a
major drawback in identifying treatments (Fidler and Goste, 1985). Heterogeneity in
apoptosis originates from variations in protein expression and protein interactions in
different colon cancer cells (Schmid et al., 2012).

Expression of NOX isoforms and regulatory proteins varies among human
colorectal cell lines. For instance, LS180 and LS174T cell lines expressed p67phox mRNA
at intermediate levels, while Caco2 and HT-29 cell lines expressed it in very low levels
(Juhasz et al., 2009). In addition, human colon cancer cells exhibit heterogeneity in
response to iodonium-class flavin dehydrogenase inhibitors (Doroshow et al., 2013).

In this chapter, we demonstrate that human colon cancer cell lines HCT116,
HCT15, SW480, DLD-1, LoVo, and MOSER vary in basal levels of NOX enzyme
activity. Furthermore, treatment of FdUrd results in differential induction of levels of the
enzyme, implicating a diverse response to TS inhibitors. Additionally, we demonstrate
that both basal and drug-induced apoptotic indices in response to FdUrd vary.
Furthermore, mRNA levels of NOX2 regulatory subunits—p67phox, p40phox and p47phox
vary significantly in both basal and FdUrd-inducible levels, thereby implicating
considerable variation among colon cancer cell lines.

3.2. RESULTS
Human colon cancer cell lines exhibit different levels of NOX activity

Human colon cancer cell lines show the wide range of genetic, morphological and
functional heterogeneity (Leibovitz et al., 1976; McBain et al., 1984; Brattain et al.,
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1981). In order to determine whether these cell lines show variations in NOX activity in
response to FdUrd, several, including HCT116, HCT15, SW480, DLD-1, LoVo and
MOSER were treated with 10µM FdUrd for 24 hours, and NOX activity measured.
HCT116 basal activity levels were set as 1 and the fold-increase of the activity in other
cell lines in the absence and presence of FdUrd was calculated. Basal levels of NOX
activity in these cell lines range from 1.2- to 4.2-fold. Following FdUrd, the activity was
increased 1.7- to 4.8-fold in lines. MOSER had the highest basal (4.2 fold, p<0.05) and
drug-inducible (4.8 fold, p<0.05) activity level among these cells. However, DLD-1 and
LoVo cell lines showed low basal (1.2- and 1.6-fold, respectively) and drug-inducible
(2.5-fold, p<0.05 and 1.7-fold, respectively) activity levels (Figure 3.1).

Apoptotic response to FdUrd varies in human colon cancer cells

Heterogeneity arising among tumor cells can lead to resistance to chemotherapeutic drugs
(de Anta et al., 2006), may be a significant impediment in effective chemotherapeutic
treatments (Fidler and Goste, 1985). It has been previously shown that apoptotic protein
expression and interactions differ in colon cancer cells (Schmid et al., 2012). Thus, we
determined if apoptotic response to FdUrd varies among different colon cancer cells. In
order to test this, HCT116, HCT15, SW480 and LoVo cells were treated with FdUrd for
24 hours, and apoptotic indices were evaluated by TUNEL assay. It was observed that
basal levels of apoptosis change from cell line to cell line. LoVo exhibited 3-fold higher
(p<0.05) basal levels relative to HCT116 cells and HCT15. Drug-mediated increases in
apoptotic indices were greater in HCT116 and HCT 15 cells (16-fold, p<0.01 and 14-
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fold, p<0.01) respectively than SW480 and LoVo cells (8-fold, p<0.01 and 6.5-fold,
p<0.01) respectively (Figure 3.2).
mRNA expressions of NOX2 accessory subunits—p67phox, p40phox and p47phox differ
in human colon cancer cell lines

It has previously been demonstrated that expression of NOX isoforms and their accessory
subunits varies in human tumor cells (Juhasz et al., 2009). Given the variation of NOX
activity levels and apoptotic responses in human colon cancer cells, we determined
whether mRNA levels of NOX2 accessory subunits—p67phox, p40phox and p47phox vary in
different colon cancer cells. Cells were treated with FdUrd for 24 hours, and expression
of the subunits was assessed by qPCR. Human colon cancer cell lines—HCT116,
HCT15, SW480, DLD-1, LoVo, MOSER and LS180 showed different basal and druginducible mRNA levels for p67phox and p40phox (Figure 3.3 and 3.4). LoVo, MOSER and
LS180 exhibited high basal levels of p67phox (p<0.05) while SW480 exhibited
intermediate levels (p<0.05). HCT116, HCT15 and DLD-1 expressed low basal levels of
p67phox. FdUrd-induced p67phox levels were seen in HCT116 and DLD-1, about 23-fold
(p<0.01) and 9-fold (p<0.05), respectively (Figure 3.3 A).
Expression of p40phox was low in HCT15, LoVo and MOSER cells compared to
HCT116, SW480, DLD-1 and LS180. FdUrd-induced p40phox levels in HCT15 and LoVo
cells, were 8- and 10-fold (p<0.05), respectively. HCT116 and MOSER cells exhibited
low levels of drug-induced p40phox levels while SW480, DLD-1 and LS180 expressed
intermediate levels (Figure 3.4).
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Basal and drug-inducible mRNA levels of p47phox also vary among the lines
(Figure 3.5). HCT116 and SW480 showed similar basal and drug-inducible mRNA levels
of p47phox. Although MOSER and LS180 exhibited similar basal levels of p47phox, druginduced levels were unchanged in MOSER, but were induced 8.5-fold (p<0.05) in LS180
cells.
Protein levels of p67phox subunits in colon cancer cells exhibited the same trend as
seen in its mRNA expression (Figure 3.3 A). Low basal levels of p67phox in several lines
could not be detected by western-blot analysis.

3.3. DISCUSSION
In chapter 1 and 2, we showed that TS inhibitors mediate increases in apoptosis
about 10 to 18-fold in HCT116 colon tumor cells (Figure 1.4 B and Figure 2.7). Here, we
demonstrate that FdUrd induce apoptosis 6.5- to 16-fold change in human colon cancer
cell lines. This different inductions result from variation in basal apoptosis levels of cell
lines, reflecting the heterogeneity in cell lines.

In chapter 2, we indicated that increases in NOX activity by TS inhibitors were
similar in HCT116, SW480 and HCT15 cell lines (Figure 2.6). However, we don’t know
how basal levels of their NOX activity change. Therefore, we determined basal and drugincreased levels of NOX activity in six different cell lines. Here, we demonstrate that
they vary in basal NOX activity levels, reflecting different backgrounds among the lines.
In response to FdUrd, increases in NOX activity were profoundly exhibited in most cell
lines, with DLD-1 and LoVo showing only slight increases.
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Our results are consistent with earlier studies, which revealed that human colon
cancer cell lines exhibit different expression levels for NOX genes (Juhasz et al., 2009).
Based on our results, the anti-tumor effects of FdUrd appear to vary among colon cancer
cell lines, reflecting phenotypic and heterogeneities. Each cell line shows different
expression levels of regulatory subunits, and different levels of NOX activity and
apoptosis levels. Therefore, deeper understanding of phenotypic features of each colon
cancer cell line could be essential to therapy of this deadly disease.
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Figure 3.1. NOX activity levels vary in human colon cancer cell lines. (A, B) HCT116,
HCT15, SW480, DLD-1, LoVo and MOSER cell lines were grown ± 10µM FdUrd for 24
hours and then were subjected to NOX activity assay. Lucigenin derived
chemiluminescence was measured by luminometer. Bars represent fold increase of
chemiluminescence ± SEM from 3 experiments (* p<0.05).
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Figure 3.2. FdUrd diversely induces apoptosis in human colon cancer cells. (A, B)
HCT116, HCT15, SW480 and LoVo cells were grown with and without 100µM FdUrd
for 24 hours. Extents of apoptosis were determined by TUNEL assay. Cells were
photographed at 400X. Bars represent fold increase of apoptotic indices ± SEM from 3
experiments (** p<0.01, * p<0.05).
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Figure 3.3. mRNA levels of p67phox vary in human colon cancer cell lines. (A, B)
qPCR was used to measure mRNA levels of p67phox in total RNA isolated from HCT116,
HCT15, SW480, DLD-1, LoVo, MOSER and LS180 cultured for 24h ± 10µM FdUrd.
GAPDH was tested as a loading control. Bars represent an average of fold increase ±
SEM from 2 experiments.
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Figure 3.4. mRNA levels of p40phox vary in human colon cancer cell lines. (A, B)
qPCR was used to measure mRNA levels of p40phox in total RNA isolated from HCT116,
HCT15, SW480, DLD-1, LoVo, MOSER and LS180 cultured for 24h ± 10µM FdUrd.
GAPDH was tested as a loading control. Bars represent an average of fold increase ±
SEM from 2 experiments.
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Figure 3.5. mRNA levels of p47phox vary in human colon cancer cells. (A, B) qPCR
was used to measure mRNA levels of p47phox in total RNA isolated from HCT116,
HCT15, SW480, DLD-1, LoVo, MOSER and LS180 cultured for 24h ± 10µM FdUrd.
GAPDH was tested as a loading control. Bars represent an average of fold increase ±
SEM from 2 experiments.
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CHAPTER 4
NFκB PLAYS A ROLE IN BASAL LEVELS OF ROS IN HCT116 CELLS
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4.1. INTRODUCTION
Nuclear factor kappa B (NFκB) is a transcription factor that binds to specific sites on
DNA and influences downstream expression of many genes involved in immune
response, apoptosis, cell proliferation, adhesion and differentiation (Perkins, 2000;
Beinke and Ley, 2004). Its function is inhibited by binding to the so-called Inhibitor of
kappa-B-α (IκBα). Activation of NFκB follows the 26S proteasome-mediated
degradation of IκBα that results from phosphorylation of IκBα by IκB kinase-β (IKKβ)
(Beinke and Ley, 2004). NFκB signaling is a central coordinator of the innate and
adaptive immune system. It is widely accepted that NFκB functions as an anti-apoptotic
factor. Consistent with this, many investigations have shown that low levels of NFκB
make cells vulnerable to the cytotoxic effects of TS inhibitors (Konishi et al., 2006;
Tafani et al., 2013; Camp et al., 2004; Li et al., 2006; Voboril et al., 2004).

In direct opposition to the generally accepted view, our laboratory has shown that
NFκB promotes apoptosis during thymidylate deprivation, implicating a pro-apoptotic
role in cells responding TS inhibitors (Barbour and Berger, 2008; Harwood et al., 2000).
Other studies have also shown a pro-apoptotic function for NFκB, implicating its dual
role in the regulation of apoptosis (Ravi et al., 2001; Kasperczyk et al., 2005). The
activation of NFκB is therefore a double-edged sword, and its function depends on
context of signaling pathways.
To show that the apoptotic response to TS inhibitors is regulated by NFκB in
human colon carcinoma cells, our lab utilized a NFκB deficient cell line, HCT116dnIkBα, and its revertent, HCT116-dnIkBα-R (Barbour and Berger, 2008). HCT11661

dnIkBα cell line is produced by stably transfecting HCT116 cells with a plasmid that
expresses a dominant-negative mutant form of IkBα. To produce HCT116-dnIkBα-R cell
line, HCT116-dnIkBα cells were passaged in non-selective media for 4 months and a
revertent clone was obtained. Experiments described in Chapters 1 and 2 indicated that
cell death mediated by TS inhibitors is ROS-dependent, and that NOX enzyme is
involved. Whether there is a link between ROS and transcription factor NFκB in
apoptotic response to TS inhibitors is unknown. Here, we demonstrate that basal ROS
levels were increased in HCT116-dnIkBα cells compared to HCT116 and HCT116dnIkBα-R cells, however; the induced levels of ROS by TS inhibitors was not
significantly changed in these cells. In addition to this finding, mRNA levels of p67phox
were increased in HCT116-dnIkBα cells compared to HCT116 and HCT116-dnIkBα-R
cells while the upregulation of p67phox mRNA by FdUrd was not significantly changed,
indicating parallel changes with levels of ROS. We also demonstrate that drug-induced
increases in NOX activity were similar in all three cells. Overall, these observations have
led to the conclusion that NFκB acts on basal, but not drug-mediated ROS levels.

4.2. RESULTS
ROS formation mediated by TS inhibitors is not NFκB-dependent
NFκB regulates the expression of many genes for immune response, cell proliferation and
differentiation, etc. Imbalance between NFκB and its inhibitor IκB has been associated
with progress of many diseases, including cancer (Beinke and Ley, 2004). It is suggested
that NFκB plays a pro-apoptotic role in apoptotic response to TS inhibitors (Barbour and
Berger, 2008; Harwood et al., 2000). To determine whether it acts on oxidative or ROS62

derived apoptotic response to TS inhibitors, we exposed parental line HCT116, NF-κB
deficient cell line, HCT116-dnIkBα, and its revertent, HCT116-dnIkBα-R to TS
inhibitors. Basal H2O2 and O2.- levels were higher in HCT116-dnIkBα cells as compared
to HCT116, and were rescued in HCT116-dnIkBα-R cells. However, both H2O2 and O2.levels induced by TS inhibitors were unchanged in all three lines (Figure 4.1).
Loss of NFκB does not alter mRNA levels of p67phox induced by FdUrd
As seen in Chapter 2, p67phox induction is associated with in drug-mediated ROS
generation in HCT116 cells (Figure 2.11 and 2.12). In order to determine if NFκB plays a
role in the induction of p67phox mRNA induced by TS inhibitors, we treated HCT116,
HCT116-dnIkBα, and HCT116-dnIkBα-R cells with inhibitors and found that loss of
NFκB increased basal levels of p67phox mRNA in HCT116-dnIkBα relative to HCT116
and HCT116-dnIkBα-R cells. However, NFκB deficiency did not significantly change
mRNA levels of p67phox in drug-treated cells (Figure 4.2).
NFκB deficiency does not affect increases in NOX activity mediated by TS inhibitors

In order to examine whether drug-mediated increases in NOX activity are altered by
NFκB, we exposed HCT116, HCT116-dnIkBα, and HCT116-dnIkBα-R cells to TS
inhibitors and measured NOX activity. We determined that loss of NFκB did not alter
increases in NOX activity mediated by TS inhibitors in any of the three cells (Figure 4.3).
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4.3. DISCUSSION
NFκB is a multipotent transcription factor that regulates cell proliferation and
differentiation, immune response, apoptosis and other integral cellular functions (Perkins,
2000; Beinke and Ley, 2004). Although several studies have reported it as having a proapoptotic role (Barbour and Berger, 2008; Harwood et al., 2000), most investigations
have indicated it to be an anti-apoptotic factor (Karin, 2006; Konishi 2006; Tafani et al.,
2013), showing its dual functions in the control of cell functions.
It is known that NFκB promotes cell death due to thymidylate deprivation
resulting from TS inhibition. However, the mechanism underlying NFκB-mediated cell
death is not well understood. Our data suggests that this does not occur via alterations in
ROS induction mediated by TS inhibitors. We have shown that HCT116-dnIkBα, NFκB
deficient, cells have high basal levels of ROS compared to HCT116 and HCT116dnIkBα-R cells. This might suggest that absence of NFκB results in abnormalities in cells
because it affects expressions of many genes in cellular metabolism, giving rise to
oxidative stress. Due to loss of NFκB, TS inhibitors do not further induce ROS
generation in HCT116-dnIkBα cells compared to HCT116 and HCT116-dnIkBα-R cells,
indicating the effect of NFκB on drug-mediated ROS generation.
We have also shown that basal levels of p67phox mRNA are increased in HCT116dnIkBα cells relative to HCT116 and HCT116-dnIkBα-R cells, but induced mRNA levels
by TS inhibitors is similar between these 3 cells. Additionally, increases in NOX activity
are also similar in these cells, indicating that under the conditions of our experiments,
NFκB has no role in NOX activity in response to TS-directed agents.
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Under certain conditions, it is suggested that pro-apoptotic role of NFκB in
thymidylate deficiency might be ROS-dependent, but it is not due to p67phox or NOX
enzyme. It will be important to reveal the mechanism by which it promotes apoptosis in
future work and to determine how the anti-apoptotic responses were silenced.
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Figure 4.1. Loss of NFκB increases basal ROS levels. HCT116, HCT116/dnIkBα and
HCT116/dnIkBα-R cells were treated with 10µM 5-FU, and 10µM FdUrd for 24 hours
and then stained by 5µM H2DCF-DA and 5µM DHE. ROS detection was done in both
fluorescence microscopy and flow cytometry. Pictures from fluorescence microscopy
represent H2O2 formation (green) and O2.- (red). Bars from flow cytometry represent fold
increase of H2O2 (DCF fluorescence) and O2.- (HE fluorescence) formation ± SEM from
3 experiments (* p<0.05, ** p<0.01).
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Figure 4.2. Basal levels of p67phox mRNA is increased by loss of NFκB. (A, B) qPCR
was used to measure mRNA levels of p67phox in total RNA isolated from HCT116,
HCT116-dnIkBα and HCT116-dnIkBα-R cell lines cultured for 24h ± 10µM 5-FU and
10µM FdUrd. GAPDH was tested as a loading control. Bars represent an average of fold
increase ± SEM from 2 experiments.
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Figure 4.3. Drug-increased NOX activity is unchanged in NFκB deficiency. (A, B)
HCT116, HCT116-dnIkBα and HCT116-dnIkBα-R cell lines were grown ± 10µM 5-FU
and 10µM FdUrd for 24 hours and then were subjected to NOX activity assay. Lucigenin
derived chemiluminescence was measured by luminometer. Bars represent fold increase
of chemiluminescence ± SEM from 3 experiments.
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CONCLUDING STATEMENTS
TS is the sole source and indispensable for de novo synthesis of thymidylate associated
with DNA synthesis and cell growth in absence of exogenous thymidine. Therefore, it
has been viewed as a significant target in the treatment of cancer for quite some time. TStargeted therapy by anti-metabolites, including TS inhibitors—5-FU, RTX, has been
effective for decades and is still mainstay in the cancer chemotherapy. Drug-mediated TS
inhibition leads to thymine-less cell death, misincorporation of uracil and thymine into
DNA and RNA, genome damage, oxidative stress and apoptosis. Effects of oxidative
stress on TS inhibitors-directed cell death are not well understood. Here, we demonstrate
that 5-FU, FdUrd and RTX induce ROS formation in human colon tumor cell line
HCT116 and the induction is attenuated by NAC, addition of thymidine and TS
overproduction, showing dependence of oxidative stress to TS inhibition. NAC also
inhibits drug-mediated cell death. NOX enzyme is identified as the primary source of
ROS following drug exposure because NOX inhibitors decreased ROS accumulation in
combination of drugs. Additionally, TS inhibitors increase the enzyme activity in
correlation with induction of p67phox mRNA expression that specifically regulates the
NOX2 isoform. Addition of thymidine and TS overproduction diminish these effects.

Other colon tumor cell lines showed variation in basal and drug-induced levels of
NOX activity and of gene expressions of NOX2 accessory subunits—p67phox, p40phox and
p47phox. They also indicate diverse basal and drug-inducible levels of apoptosis,
implicating cell specific responses to drugs. Drug-induced ROS generation in correlation
with induction of p67phox mRNA expression is not NFκB dependent. In absence of NFκB,
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basal levels of ROS and p67phox mRNA expression are increased in HCT116 cells,
showing independent oxidative stress resulted from different mechanisms.

Based on the findings herein reported, a model was developed to illustrate the
origin and role of ROS in cell death mediated by TS inhibitors (Figure C1). These
findings shed light on understanding of drug effects in cell death since how TS inhibitors
kill cells is ill-defined. While our results clearly demonstrate a correlation between druginduced ROS generation and apoptosis, NOX activity, and p67phox expression, they also
raise several questions. First, it is not clear how these results are linked to each other. It
would be necessary to knockdown or overexpress the p67phox subunit in order to
determine if it regulates drug-induced ROS production, apoptosis, and NOX activity.
Second, we don’t know how upregulation of p67phox subunit by drugs impacts protein
function. Is there a linear relationship between protein expression and function? If not,
what are the factors mediating the function?

A third question rising from our results is whether or not expression of other NOX
isoforms, i.e., NOX3-5, is altered in response to drugs. We also don’t know which
isoform(s) results in drug-increased NOX activity. It would be interesting to investigate
which isoform(s) is targeted by TS inhibitors.

Our results also showed that, in addition to ROS induction, drug exposure
increased expressions of some Nrf2 target genes which are the major defense response
against oxidative stress, implicating dual impacts of drugs in colon cancer cells. If TS
inhibitors are combined with drugs that inhibit the defense system, cells may become
more sensitive to ROS-derived apoptosis. Future studies should reveal detailed
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mechanisms of drug-mediated ROS generation and the antioxidant responses in colon
cancer cells. At the mechanistic level, future studies should focus on other ROS sources,
in addition to NOX, involved in oxidative stress-derived apoptotic response to drugs.

Figure C1. Model for the role of drug-mediated ROS in cell death. TS inhibitors
deplete thymidylate levels following DNA damage. Increase in NOX2 activity correlated
with induction of p67phox results in further ROS generation and genome damage. If such
damage mediated by “feed-forward” death loop is over tolerable threshold, cells undergo
programmed cell death. These effects are inhibited by exogenous addition of thymidine
or TS overproduction. NFκB inhibits ROS formation induced by NOX2 in correlation
with the induction of p67phox.
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CHAPTER 5
MATERIALS AND METHODS
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Cell culture

Human colon tumor cell line HCT116 was kindly obtained from Dr. Michael G. Brattain.
HCT116/200 is TS-overproducing derivative of HCT116 and has been previously
described (Berger et al., 1988). Other human colon cancer cell lines SW480, HCT15,
LoVo, DLD-1, MOSER and LS180 are obtained from American Type Culture Collection
(ATCC); (Manassas, VA). NFκB-deficient cell line, HCT116/dnIκB, and its revertent cell
line, HCT116/dnIκB-R were previously described (Barbour and Berger, 2008). Cells
were grown in RPMI-1640 medium (Cellgro) supplemented with 10% heat-activated
fetal bovine serum (FBS, Atlanta Biologicals) at 37°C in a humidified 5% CO2
atmosphere. Additionally, HCT116/dnIκB cells were grown with 1mg/ml G418
(FisherBiotech, Fair Lawn, N.J.) to stabilize clone.

Drug Treatment

HCT116 and HCT116/200 cells were treated with TS inhibitors; 5-FU, FdUrd (SigmaAldrich Co., St. Louis, MO, USA) and RTX (AstraZeneca, Macclesfield, Cheshire, UK)
for the indicated concentrations and times. 10µM folinic acid (leucovorin, Sigma-Aldrich
Co., St. Louis, MO, USA) was combined with 5-FU and FdUrd treatments in every time.
NAC, Thy (Sigma-Aldrich Co., St. Louis, MO, USA), Apocynin (APO, Acros Organics
Inc., Geel, Belgium), ATZ (Chem Service, West Chester, PA, USA) and VAS-2870
(Enzo Life Sciences Inc., Plymouth Meeting, PA, USA) are combined with TS inhibitors
and co-incubated. Diphenyleneiodonium (DPI, Calbiochem/EMD Biosciences, San
Diego, CA, USA) is pretreated to HCT116 cells for 3h. After that, cells were washed
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twice with Hanks solution (Cellgro Mediatech Inc., Manassas, VA) and treated with TS
inhibitors for 24h.

Fluorescence Microscopy

Intracellular ROS production was measured by oxidation of cell permeable dyes
H2DCFDA and DHE (Invitrogen/Molecular Probes Inc., Eugene, OR, USA) to
fluorescent DCF by H2O2 and to fluorescent 2-hydroxyethidium (HE) by O2.respectively. Cells were grown to 60% confluence in chamber slides (VWR International
LLC., Suwanee, GA, USA). After incubation, they were washed twice with PBS and
were fixed in 4% paraformaldehyde (Alfa Aesar, Ward Hill, MA, USA) for 30 min at
room temperature. Cells were washed twice with PBS and separately stained with 5µM
H2DCFDA and DHE in dark followed incubation at 37°C for 30 min. Slides were kept in
dark after this point. After incubation, cells were washed twice with PBS and chambers
were separated from slides by slide separator. Coverslips were mounted on glass slides
using permount medium (Fisher Scientific, Fair Lawn, New Jersey, USA). Images were
acquired at room temperature using an inverted microscope (Axiovert 200, Carl Zeiss)
equipped with a Plan-Apo 63×/1.40 objective and a charge-coupled camera (AxioCam
HRm, Carl Zeiss) linked to AxioVision software (version 4.7, Carl Zeiss). To get the best
visual reproduction, the image input levels were adjusted by stretching the histogram. In
this point, Image brightness and linearity were sustained. To analyze changes in DCF and
HE fluorescence, ImageJ software (National Institutes of Health) was used to get
fluorescence in numbers. Analysis of DCF and HE fluorescence was done by selecting
cells with a pixel range for brightness and by subtracting background stained.
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Flow Cytometry

Cells were grown to 80% confluence in 60mm plates. After incubation, they were washed
twice and suspended with fluorescence-activated cell-sorting (FACS) staining buffer
(PBS with 1% BSA). 0.5µM H2DCFDA and DHE dyes were separately applied to cells
for at 37°C for 15min in dark. After this point, cells were kept in dark. They were washed
twice, suspended with FACS buffer and analyzed by flow cytometer (FC 500 by
Beckman Coulter Fort Collins Co). Histograms were analyzed in CXP software by
obtaining X-mean value for each treatment. From 3 separate experiments, average Xmean was calculated for each treatment and data was normalized in fold increase of drug
treatments to control.

Measurement of Apoptotic and Necrotic Cell Death

To determine apoptotic cells, terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) assays were applied using the In Situ Cell Death Detection Kit,
POD (Roche Applied Science, Indianapolis, IN, USA). Cells were stained with regard to
the manufacturer’s instructions following hematoxylin counterstaining and observed
under a light microscope at 400X magnification. Cells exhibited brown nuclear staining
that might be very dark after labeling since they contain fragmented nuclear chromatin
characteristic of apoptosis. Based on staining, 1000 cells, both attached and non-attached,
were counted manually for each treatment so as to calculate apoptotic content as the
proportion of apoptotic/total cells.

75

NADPH Oxidase Assay
Cells were washed twice with PBS after incubation. 105 cells for each cell line and
treatment were suspended in 500µl reaction buffer [50mM phosphate buffer (pH 7.0),
1mM EGTA (Research Organics, Cleveland, OH, USA), 150mM sucrose (Mallinckrodt
Chemical, Paris, KY, USA)]. 100µM NADPH (Calbiochem/EMD Biosciences, San
Diego, CA, USA) was added as substrate. Light sensitive 5µM lucigenin (Enzo Life
Sciences Inc., Plymouth Meeting, PA, USA) was added to reaction mixture in dark. Cells
were kept in dark after this point and incubated at 37°C for 10min. Negative controls like
adding only NADPH to the reaction mixture without cells and adding only cells to the
mixture without NADPH were prepared. After incubation, NADPH oxidase activity was
immediately detected by lucigenin-derived chemiluminescence using a luminometer
(GloMax-20/20 luminometer, Promega, Madison, WI, USA). The levels of emitted
chemiluminescence in every 15s for 1min of measurement were saved for each treatment.
The signal reading was normalized by subtracting chemiluminescence obtained from
negative controls and expressed as arbitrary light units per 105 cells.

Microarray Analysis

RNA Isolation from HCT116 Cells: Cells were treated in quadruplicate with 10 µM of
5-FU for 24 hours. According to the recommendations of the manufacturer, total RNA
was isolated from 6 x 106 cells using RNeasy Mini Kit (Qiagen, Maryland, USA) by
additionally applying RNase Free DNase Set (Qiagen, Hilden, Germany) to eliminate
contaminating genomic DNA. The integrity and concentration of the total RNA was
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assessed on a 2100 Bioanalyzer (Agilent Biotechnologies), using the RNA 6000 Nano
LabChip. The RNA integrity number range from 9.8 to 10.0.

mRNA Labeling and Hybridization: Microarrays experiments were performed using
Agilent’s platform. Total RNA samples isolated from HCT116 cells were amplified and
labeled using Agilent’s Low Input Quick Amp Labeling Kit (Cat. # 5190-2306)
according to the manufacturer recommendations. Briefly, mRNA contained in 200ng of
total RNA was converted into cDNA using a poly-dT primer that also contained the T7
RNA polymerase promoter sequence. Subsequently, T7 RNA polymerase was added to
cDNA samples to amplify original mRNA molecules and to simultaneously incorporate
cyanine 3- or cyanine 5-labeled CTP (cRNA) into the amplification product. In addition,
Agilent RNA spike-in controls (Cat. # 5188-5279) were added to samples prior to cDNA
synthesis and were used as experimental quality control. In the next step, labeled RNA
molecules were purified using Qiagen’s RNeasy Mini Kit (Cat. # 74104). After
spectrophotometric assessment of dye incorporation and cRNA yield, samples were store
at -80°C until hybridization. Labeled cRNA samples were hybridized to Agilent Human
GE 4 x 44K v2 Microarrays (Cat. # G4845A) at 65°C for 17 hours using Agilent’s Gene
Expression Hybridization Kit (Cat. # 5188-5242) according to the manufacturer’s
recommendations. Four (4) control sample replicates we hybridized against four (4) 5-FU
treated sample replicates in a dye swap design. After washes, arrays were scanned using
an Agilent DNA Microarray Scanner System (Cat. # G2565CA).

Data analysis: Data was extracted from images with Feature Extractor Software version
10.7.3.1 (Agilent). In this process, background correction using additive and
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multiplicative detrending algorithms was performed. In addition, linear and LOWESS
methods were used for dye normalization. Subsequently, background-corrected, dyenormalized data was uploaded into GeneSpring GX version 11.5.1 for analysis. In this
process, data was log2 transformed, quantile normalized and base line transformed using
the median of all samples. Then, data was filtered by flags in a way that 100% of the
samples in at least one of the two treatment groups have a “detected” flag. Differentially
expressed genes were determined by analysis of the data using an unpaired t-test statistics
that was corrected for multiple testing using the Benjamini-Hochberg algorithm. A cutoff
p-value of 0.005 was used. Additionally, a fold change cutoff value of 1.5 was used to
filter the data

Semi-quantitative RT-PCR

After each treatment, total RNA was isolated using RNeasy Mini Kit (Qiagen, Maryland,
USA) by additionally applying RNase Free DNase Set (Qiagen, Hilden, Germany) to
eliminate contaminating genomic DNA. RNA concentration was spectrophotometrically
measured at 260 and 280nm absorbance (NanoDrop ND-1000 Spectrophotometer,
Thermo Fisher Scientific, USA). For each reaction, 1µg RNA was reversely transcribed
in a Mycycler Thermal Cycler (Biorad, Hercules, CA) with iscript cDNA synthesis kit
(Biorad, Hercules, CA, USA) according to manufacturer procedures. The reactions were
incubated for 5 min in 25°C, 30 min in 42°C, heated for 5 min in 85°C and hold at 4°C.
The relative expression of each gene was assessed in indicated PCR cycles. Controls with
no reverse transcriptase enzyme and no template RNA were used to check contamination
in each gene. The different PCR tubes within each series were set up such that they went
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through PCR for increasing numbers of amplification cycles. The PCR reactions for each
gene were run with 1 μl of cDNA and 250ng primers (Table 1, Integrated DNA
Technologies Inc., Coralville, IA, USA) in a total volume of 25 μl, using GoTaq Hot
Start Green Master Mix (Promega, Madison, WI, USA).

All PCR reactions comprised an initial denaturation step for 2 min at 95°C and
followed by denaturation (30s at 95°C), extension (30s at 72°C) and final extension step
(5 min at 72°C). Annealing step was 30s at 50°C for GAPDH, Rac1, NOXA1, gp91 and
p67phox; at 49.5°C for p47phox; at 60°C for NOXO1 and at 52°C for NOX1. Amplification
cycles were from 18 to 33 for GAPDH and Rac1 and 32 to 44 for other genes. The
amplified cDNA products were resolved by 1.5% (w/v) agarose gel electrophoresis and
visualized by staining with ethidium bromide (Sigma-Aldrich Co., St. Louis, MO, USA).

Quantitative PCR
According to the manufacturer’s suggestions, cDNA (1μl) was amplified using Power
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). Reactions were
run for one cycle at 95°C for 10 min, and 40 cycles of 95°C for 15s, 50°C for 15s and
72°C for 40s using an Applied Biosystems 7300 Real Time PCR System. All mRNA
levels were quantified relative to GAPDH by measuring SYBR green incorporation
during quantitative PCR using the relative standard curve method. Statistical analyses and
calculations were done as described in the manufacturer’s protocol. Relative changes in
each gene levels between drug-treated and nontreated cells are expressed as fold
induction compared with the basal level of expression in nontreated cells. Primers
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(Integrated DNA Technologies Inc., Coralville, IA, USA) used for qPCR are listed in
Table 2.

Western Blotting
Cells were lysed in M-PER® mammalian protein extraction reagent (Thermo scientific,
Rockford, IL, USA) and protein content was determined colorimetrically using the
Bradford assay (Bio-Rad, Hercules, CA, USA) with BSA as protein standart. Lysates
(100 µg) were run on by 12.5% Tris/HCl (Bio-Rad), electrophoresed in running SDSPAGE buffer, transferred to PVDF membranes and probed with anti-p67phox goat
polyclonal antibody (sc7662, C-19, Santa Cruz, Dallas, TX, USA) at a dilution of 1:200
in 3% non-fat milk in PBS/0.05% Tween for 1 hour at room temperature. The membrane
was washed three times for 10 min with PBS/0.05% Tween before and after incubated
with appropriate secondary antibody for 1 hour at room temperature. ECL kit (GE
Healthcare Life Sciences, Amersham ECL, Pittsburgh, PA, USA) was used to visualize
the antigen-antibody complexes by chemiluminescence after washing the membrane.

Statistical Analysis

All data were reported as the mean ± SEM. Statistical significance of the mean for each
groups were determined using student’s t-test. Differences with P ≤ 0.05 were considered
statistically significant.
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Table 5.1. Primers used for semi-quantitative RT-PCR
Primer (F:5’-3’, R:5’-3’)
F: ATGGAGCGCTGGGGACAGAAGTACATG
R: GATGGTGCCTCCGATCTGCGGCCG
gp91
F: TGGTACACACATCATCTCTTTGTG
R: AAAGGGCCCATCAAGCGCTATCTTAGGTAG
NOX1 F: TGAAGGACCTCTCCAGAATC
R: CAGGTGTGCAATGATGTG
p47phox F: ACCCAGCCAGCACTATGTGT
R: AGTAGCCTGTGACGTCGTCT
phox
p67
F: CGAGGGAACCAGCTGATAGA
R: CATGGGAACACTGAGCTTCA
NOXO1 F: GGCAGCCCTGGTGCAGATCAAGAGGC
R: CAGTCGCCAGCAGCCTCCGAGAATAGG
NOXA1 F: CCATCGACTACACGCAGCT
R: GTAGGCAGTCGACGTGCAGC
Rac1
F: GGTGAATCTGGGCTTATGGG
R: CTAGACCCTGCGGATAGGTG
GAPDH F: ACCACCATGGAGAAGGCTGG
R: CTCAGTGTAGCCCAGGATGC
mRNA
p22

Product Size (bp)
252
558
434
767
747
281
467
280
528

Table 5.2. Primers used for qPCR
Primer (F:5’-3’, R:5’-3’)
F: ATGGAGCGCTGGGGACAGAAGTACATG
R: GATGGTGCCTCCGATCTGCGGCCG
gp91
F: TGGTACACACATCATCTCTTTGTG
R: AAAGGGCCCATCAAGCGCTATCTTAGGTAG
NOX1 F: CTCCCTTGCCTCCATTCTC
R: AGGCTATTGTCATGATCACTCC
phox
p40
F: AAAGTCAAGAGCGTGTCCC
R: GAGGAAGATCACATCTCCAGC
p47phox F: ACACCTTCATCCGTCACATC
R: GAACTCGTAGATCTCGGTGAAG
p67phox F: CGAGGGAACCAGCTGATAGA
R: CATGGGAACACTGAGCTTCA
NOXO1 F: AGATCAAGAGGCTCCAAACG
R: AGGTCTCCTTGAGGGTCTTC
NOXA1 F: CAGGCTGTGGATCGTGG
R: CACGGCTTGGTCAAATGC
Rac1
F: GGTGAATCTGGGCTTATGGG
R: CTAGACCCTGCGGATAGGTG
GAPDH F: ACCACCATGGAGAAGGCTGG
R: CTCAGTGTAGCCCAGGATGC
mRNA
p22
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Product Size (bp)
77
94
149
132
143
131
117
150
82
218
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